The utilization of artificial intelligence (“AI”) is becoming ubiquitous across a wide range of industry sectors. The biotech industry is
Continue Reading Key Inventorship Considerations in AI-assisted Drug DevelopmentDan Shores
Dan Shores is a Partner at Rothwell Figg and is a founder of its Boston office. He is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay, their daughter Audrey, and their two English Bulldogs Jarves and Rosie.
Advanced IP Considerations for Cell-and-Gene Therapeutic Companies Utilizing Lipid Nanoparticle Delivery Systems
As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage…
Continue Reading Advanced IP Considerations for Cell-and-Gene Therapeutic Companies Utilizing Lipid Nanoparticle Delivery SystemsmRNA IP 2022 Year in Review: Pioneers Clash in Major Patent Litigations
Substantial patent litigation activity occurred in the mRNA space in 2022, involving nearly all of the major mRNA and lipid…
Continue Reading mRNA IP 2022 Year in Review: Pioneers Clash in Major Patent LitigationsThe Current mRNA/LNP Patent Litigation Landscape
Several patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the…
Continue Reading The Current mRNA/LNP Patent Litigation Landscape
Merck and Orna Therapeutics Join Forces in Circular RNA Collaboration
On August 16, 2022, Merck (NYSE: MRK) and Orna Therapeutics each announced that they entered into a collaboration agreement relating…
Continue Reading Merck and Orna Therapeutics Join Forces in Circular RNA Collaboration
Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space
In the first major patent infringement lawsuit in the mRNA space, on February 28, 2022, Arbutus Biopharma Corporation (“Arbutus”) and…
Continue Reading Arbutus and Genevant Sue Moderna in First Significant Patent Infringement Lawsuit in the mRNA Space
Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”
On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics,…
Continue Reading Delaware Judge Denies Sarepta Protection Under Hatch-Waxman “Safe Harbor”
mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market.
Continue Reading mRNA Patent and Competitive Landscape: 2021 Year in Review and 2022 Outlook
Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Introduction
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each…
Continue Reading Three (3) Initial Considerations for Entrepreneurial Faculty, Researchers, Post-Docs, and Graduate Students
Alphabet Dives Further Into AI-Driven Drug Discovery
Google’s parent company Alphabet announced the launch of a new company this week dedicated to applying deep learning methods to…
Continue Reading Alphabet Dives Further Into AI-Driven Drug Discovery